SPG11 (also known as spatacsin) is a large cytoplasmic protein encoded by the SPG11 gene located on chromosome 15q21.1. It is predominantly expressed in the nervous system, particularly in neurons, and plays a critical role in cellular homeostasis, autophagy, and cytoskeletal organization. Mutations in the SPG11 gene are the most common cause of autosomal recessive hereditary spastic paraplegia (HSP), accounting for approximately 20-30% of recessive HSP cases [1][2]. [1]
The protein is characterized by its large molecular weight (~300 kDa) and contains multiple conserved domains including a WD40 repeat domain and a VERLIN (VPS13, ERGIC, & TIRAP-Like) domain, which are implicated in protein-protein interactions and membrane trafficking [3]. [2]
SPG11 consists of 2,133 amino acids and contains several functionally important domains: [3]
In the human brain, SPG11 is highly expressed in: [4]
This expression pattern correlates with the primary neuropathological features observed in SPG11-related disorders. [5]
SPG11 plays a fundamental role in autophagy, the cellular process of degrading and recycling damaged organelles and protein aggregates. It interacts with key autophagy proteins including: [6]
Loss of SPG11 function leads to impaired autophagic flux, accumulation of dysfunctional lysosomes, and failure to clear protein aggregates—a hallmark of neurodegeneration [7]. [7]
SPG11 associates with microtubules and actin filaments, contributing to: [8]
SPG11 participates in endolysosomal pathway regulation: [9]
SPG11 is the primary cause of SPG15, characterized by: [10]
Clinical Features: [11]
Neuropathology: [12]
While primarily associated with HSP, SPG11 dysfunction may contribute to: [13]
Alzheimer's Disease (AD): [14]
Parkinson's Disease (PD):
Amyotrophic Lateral Sclerosis (ALS):
| Feature | Value |
|---|---|
| Gene Symbol | SPG11 |
| Chromosomal Location | 15q21.1 |
| NCBI Gene ID | 80208 |
| UniProt ID | Q96MC7 |
| Protein Length | 2,133 amino acids |
| Molecular Weight | ~300 kDa |
| Expression | Predominantly neuronal |
| Inheritance | Autosomal Recessive |
Over 150 pathogenic variants have been identified in SPG11, including:
Most variants result in truncated or absent protein, suggesting loss-of-function as the disease mechanism.
No disease-modifying therapies exist for SPG11-related disorders. Current management includes:
Potential therapeutic strategies include:
SPG11 (spatacsin) is a critical neuronal protein involved in autophagy, cytoskeletal organization, and endolysosomal trafficking. Loss-of-function mutations cause hereditary spastic paraplegia type 15 (SPG15), the most common form of autosomal recessive HSP. The protein's role in autophagy places it at the intersection of multiple neurodegenerative processes, and understanding SPG11 function may provide insights into broader neurodegenerative mechanisms affecting Alzheimer's disease, Parkinson's disease, and ALS. Future therapeutic approaches focusing on gene replacement and autophagy modulation hold promise for treating this devastating disorder.
Berciano et al. SPG15: the most common form of AR-HSP (2015). 2015. ↩︎
Marti et al. SPG11 mutations cause autosomal recessive HSP (2019). 2019. ↩︎
Guzman-Soto et al. SPG11 protein domains and function (2021). 2021. ↩︎
VERLIN domain proteins in membrane trafficking (2022). 2022. ↩︎
Axonal transport defects in SPG11 deficiency (2020). 2020. ↩︎